• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by CEO & President Alam John J

    6/25/25 5:05:20 PM ET
    $CRVO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CRVO alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    ALAM JOHN J

    (Last) (First) (Middle)
    20 PARK PLAZA, SUITE 424

    (Street)
    BOSTON MA 02116

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    CervoMed Inc. [ CRVO ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director X 10% Owner
    X Officer (give title below) Other (specify below)
    CEO & President
    3. Date of Earliest Transaction (Month/Day/Year)
    06/23/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (Right to Buy)(1) $6.52 06/23/2025 A 8,100 (2) 06/23/2035 Common Stock 8,100 $0 8,100 I By Spouse
    Explanation of Responses:
    1. Consists of an option to purchase shares of common stock granted to Sylvie Gregoire, PharmD., the Reporting Person's spouse and a non-employee director of the Issuer. The Reporting Person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
    2. The shares of common stock underlying the award will vest on a monthly basis over a one-year period in substantially equal 1/12th increments on the last day of each month beginning on June 30, 2025, subject to the Dr. Gregoire's continued service through the applicable vesting date.
    /s/ William R. Elder, attorney-in-fact for the Reporting Person 06/25/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $CRVO alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CRVO

    DatePrice TargetRatingAnalyst
    3/13/2025$14.00Neutral → Buy
    Chardan Capital Markets
    12/17/2024Buy → Neutral
    H.C. Wainwright
    12/11/2024Buy → Neutral
    Chardan Capital Markets
    12/11/2024Overweight → Underweight
    Morgan Stanley
    12/10/2024Buy → Hold
    D. Boral Capital
    12/6/2024$45.00Buy
    ROTH MKM
    12/5/2024$42.00Buy
    H.C. Wainwright
    9/18/2024$55.00Buy
    Chardan Capital Markets
    More analyst ratings

    $CRVO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    CervoMed Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

    Reported 32-week data from Phase 2b RewinD-LB Trial Extension phase showing neflamapimod treatment resulted in a substantial reduction in clinically significant worsening compared to control arm over 32 weeks, which improved further among patients who have minimal evidence of Alzheimer's disease (AD) co-pathology (ptau181 < 2.2 pg/mL at screening) At week 32 of the Extension phase, patients treated with neflamapimod demonstrated a significant reduction from baseline in plasma levels of glial fibrillary acidic protein (GFAP) Plan to engage with U.S. Food and Drug Administration (FDA) in the fourth quarter of 2025 to align on trial design for the Phase 3 program in Dementia with Lewy Bodies

    8/11/25 8:00:00 AM ET
    $CRVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CervoMed to Participate in the Canaccord Genuity 45th Annual Growth Conference

    BOSTON, Aug. 05, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that Company management will participate in a fireside chat and one-on-one investor meetings at the CG 45th Annual Growth Conference being held in Boston, MA, on Tuesday, August 12 to Thursday, August 14, 2025. Presentation DetailsFormat: Fireside ChatDate: Tuesday, August 12, 2025Time: 2:00 PM ETWebcast Link: https://wsw.com/webcast/canaccord108/crvo/2537558 The webcast of the fireside chat will be accessible in the Investor section of the CervoMed website https://www.cervomed.com/. About CervoMedCervoMed

    8/5/25 8:00:00 AM ET
    $CRVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CervoMed Announces 32-Week Data from RewinD-LB Trial Extension Phase Showing Neflamapimod's Sustained Effect on Slowing Clinical Progression in Patients with Dementia with Lewy Bodies and Associated Reduction in a Key Plasma Biomarker of Neurodegeneration

    Based on the primary endpoint of Clinical Dementia Rating Sum of Boxes (CDR-SB), patients treated with neflamapimod showed 54% risk reduction in clinically significant worsening compared to control at Week 32 of treatment (p=0.0037). This risk reduction improved to 64% (p=0.0001) among patients who have minimal evidence of AD co-pathology (ptau181 < 2.2 pg/mL at screening) At week 32 of the Extension phase, patients treated with neflamapimod demonstrated a significant reduction from baseline in plasma levels of glial fibrillary acidic protein (GFAP) Conference call and webcast today at 8:00 AM ET today to discuss results BOSTON, July 28, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc

    7/28/25 7:00:00 AM ET
    $CRVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CRVO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by CEO & President Alam John J

    4 - CervoMed Inc. (0001053691) (Issuer)

    6/25/25 5:05:20 PM ET
    $CRVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Zavrl Frank

    4 - CervoMed Inc. (0001053691) (Issuer)

    6/25/25 5:04:25 PM ET
    $CRVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Boger Joshua S

    4 - CervoMed Inc. (0001053691) (Issuer)

    6/25/25 5:03:28 PM ET
    $CRVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CRVO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    CervoMed upgraded by Chardan Capital Markets with a new price target

    Chardan Capital Markets upgraded CervoMed from Neutral to Buy and set a new price target of $14.00

    3/13/25 7:28:49 AM ET
    $CRVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CervoMed downgraded by H.C. Wainwright

    H.C. Wainwright downgraded CervoMed from Buy to Neutral

    12/17/24 7:40:50 AM ET
    $CRVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CervoMed downgraded by Chardan Capital Markets

    Chardan Capital Markets downgraded CervoMed from Buy to Neutral

    12/11/24 7:28:58 AM ET
    $CRVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CRVO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CFO, GC & Secretary Elder William Robert bought $35,811 worth of shares (4,233 units at $8.46), increasing direct ownership by 334% to 5,500 units (SEC Form 4)

    4 - CervoMed Inc. (0001053691) (Issuer)

    5/14/25 4:11:47 PM ET
    $CRVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CFO & GC Elder William Robert bought $18,160 worth of shares (1,000 units at $18.16), increasing direct ownership by 375% to 1,267 units (SEC Form 4)

    4 - CervoMed Inc. (0001053691) (Issuer)

    8/27/24 4:09:50 PM ET
    $CRVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CRVO
    SEC Filings

    View All

    CervoMed Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - CervoMed Inc. (0001053691) (Filer)

    8/11/25 8:14:32 AM ET
    $CRVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by CervoMed Inc.

    10-Q - CervoMed Inc. (0001053691) (Filer)

    8/8/25 9:18:30 AM ET
    $CRVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CervoMed Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - CervoMed Inc. (0001053691) (Filer)

    8/5/25 4:05:36 PM ET
    $CRVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CRVO
    Leadership Updates

    Live Leadership Updates

    View All

    CervoMed to Appoint William Elder as Chief Financial Officer

    BOSTON, May 20, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced the appointment of William (Bill) Elder as Chief Financial Officer, effective June 1, 2024. Mr. Elder will continue to serve as General Counsel and Corporate Secretary. He will succeed William Tanner who has served as Chief Financial Officer to CervoMed and its predecessor, EIP Pharma, since September 2022. Mr. Tanner will continue as a consultant to CervoMed following the transition. "Bill's deep biopharmaceutical and financial expertise and strong track record of enhancing operational capabilities makes him

    5/20/24 8:00:00 AM ET
    $CRVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates

    - Announced private placement of up to $149.4 million led by RA Capital Management with participation from Armistice Capital, Special Situations Funds and Soleus Capital; pro forma cash and cash equivalents from upfront proceeds expected to provide runway through the end of 2025 - CervoMed on track to complete enrollment in 2Q 2024 in its RewinD-LB Phase 2b clinical trial evaluating neflamapimod in patients with dementia with Lewy bodies (DLB); topline data expected in 4Q 2024 - Integrated summary of results from AscenD-LB Phase 2a trial published in peer-reviewed journal and presentations at a major scientific conference further inform on the potential of neflamapimod in DLB and proba

    4/1/24 8:00:00 AM ET
    $CRVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CervoMed Announces Appointment of Industry Leader Joshua Boger, Ph.D., as Chair of the Board

    Dr. Boger is the founder, and retired CEO and Board Chair, of Vertex Pharmaceuticals CervoMed on track to complete enrollment in 1H 2024 in its RewinD-LB Phase 2b clinical trial evaluating neflamapimod in patients with dementia with Lewy bodies; topline data expected in 2H 2024 BOSTON, Feb. 07, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO), a clinical-stage company developing treatments for degenerative diseases of the brain, today announced the appointment of Joshua Boger, Ph.D., to its Board of Directors (Board) and as Chair of the Board. Dr. Boger is an innovative scientist and highly successful business executive who brings extensive drug development and biopharmaceutical comp

    2/7/24 8:30:00 AM ET
    $CRVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CRVO
    Financials

    Live finance-specific insights

    View All

    CervoMed Announces 32-Week Data from RewinD-LB Trial Extension Phase Showing Neflamapimod's Sustained Effect on Slowing Clinical Progression in Patients with Dementia with Lewy Bodies and Associated Reduction in a Key Plasma Biomarker of Neurodegeneration

    Based on the primary endpoint of Clinical Dementia Rating Sum of Boxes (CDR-SB), patients treated with neflamapimod showed 54% risk reduction in clinically significant worsening compared to control at Week 32 of treatment (p=0.0037). This risk reduction improved to 64% (p=0.0001) among patients who have minimal evidence of AD co-pathology (ptau181 < 2.2 pg/mL at screening) At week 32 of the Extension phase, patients treated with neflamapimod demonstrated a significant reduction from baseline in plasma levels of glial fibrillary acidic protein (GFAP) Conference call and webcast today at 8:00 AM ET today to discuss results BOSTON, July 28, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc

    7/28/25 7:00:00 AM ET
    $CRVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CervoMed to Present New Data from Phase 2b RewinD-LB Study at AAIC 2025 and Host Conference Call on July 28, 2025

    Company to share primary endpoint results at 32-Weeks from Extension phase following late-breaking presentations at Alzheimer's Association International Conference® (AAIC) 2025 Conference call and webcast to be held Monday, July 28 at 8:00 AM ET BOSTON, July 24, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that the Company will host a conference call and webcast on Monday, July 28 at 8:00 AM ET to share new results, including the primary endpoint results at 32-weeks of the Extension phase, from the Phase 2b RewinD-LB study of neflamapimod in dementia with Lewy bod

    7/24/25 4:05:00 PM ET
    $CRVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CervoMed Announces Positive Results from the Extension Phase of its Phase 2b Clinical Study of Neflamapimod in Patients with Dementia with Lewy Bodies

    A new batch of neflamapimod capsules led to increased plasma drug concentrations and demonstrated improvement (p<0.001 vs. old capsules; p=0.003 vs. placebo) on the primary outcome measure, change from baseline in Clinical Dementia Rating Sum of Boxes (CDR-SB) Improvement (p=0.035 against either old capsules or placebo) also demonstrated on the Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change (CGIC) Compared to either old capsules or placebo, a lower incidence of falls was seen in participants receiving study drug from the new batch of capsules during the extension phase Company to host investor webcast at 5:00 PM ET today to discuss results BOSTON, March 10,

    3/10/25 4:05:00 PM ET
    $CRVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CRVO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by CervoMed Inc.

    SC 13G - CervoMed Inc. (0001053691) (Subject)

    11/14/24 3:09:10 PM ET
    $CRVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by CervoMed Inc.

    SC 13G - CervoMed Inc. (0001053691) (Subject)

    4/11/24 7:55:23 PM ET
    $CRVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by CervoMed Inc. (Amendment)

    SC 13G/A - CervoMed Inc. (0001053691) (Subject)

    3/6/24 4:05:55 PM ET
    $CRVO
    Biotechnology: Pharmaceutical Preparations
    Health Care